Skip to main
BBOT

BBOT Stock Forecast & Price Target

BBOT Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BridgeBio Oncology Therapeutics Inc. is poised for a positive financial outlook due to its robust pipeline of oncology therapies, particularly the combination of BBO-8520 with BBO-10203, which has shown promise in clinical trials by overcoming G12Ci resistance. The company's focus on addressing significant unmet medical needs in the oncology space, particularly for patients without specific PI3K mutations, expands its total addressable market (TAM) and underpins the premium valuation justifiably assigned to it compared to its small/mid-cap peers. Furthermore, with three wholly-owned assets in Phase 1 clinical trials and early data suggesting strong efficacy and safety profiles, BBOT is well-positioned for future growth within the biotechnology sector.

Bears say

BridgeBio Oncology faces significant risks that contribute to a negative outlook, primarily due to potential underperformance in its clinical trials for BBO-8520, BBO-10203, and BBO-11818, which could lead to reduced market penetration and increased discount rates. Additionally, the decreasing median progression-free survival (mPFS) rates observed in Phase 3 studies for competitive products indicate challenges in the company's ability to compete effectively in the oncology market. Further uncertainties arise from potential better-than-expected competitor products and inadequate reimbursement strategies, which could adversely affect the company's commercialization efforts and overall revenue projections.

BBOT has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BridgeBio Oncology Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BridgeBio Oncology Therapeutics Inc (BBOT) Forecast

Analysts have given BBOT a Buy based on their latest research and market trends.

According to 7 analysts, BBOT has a Buy consensus rating as of Mar 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BridgeBio Oncology Therapeutics Inc (BBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.